These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24036898)

  • 21. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α2δ1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer.
    Yu J; Wang S; Zhao W; Duan J; Wang Z; Chen H; Tian Y; Wang D; Zhao J; An T; Bai H; Wu M; Wang J
    Clin Cancer Res; 2018 May; 24(9):2148-2158. PubMed ID: 29437792
    [No Abstract]   [Full Text] [Related]  

  • 23. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
    Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
    Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
    Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
    Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study.
    Zhang N; Liu L; Dumitru CD; Cummings NR; Cukan M; Jiang Y; Li Y; Li F; Mitchell T; Mallem MR; Ou Y; Patel RN; Vo K; Wang H; Burnina I; Choi BK; Huber HE; Stadheim TA; Zha D
    MAbs; 2011; 3(3):289-98. PubMed ID: 21487242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.
    Lin S; Zhang Y; Yao J; Yang J; Qiu Y; Zhu Z; Hua H
    J Transl Med; 2024 Aug; 22(1):766. PubMed ID: 39143619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
    Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
    MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.
    Meder L; Schuldt P; Thelen M; Schmitt A; Dietlein F; Klein S; Borchmann S; Wennhold K; Vlasic I; Oberbeck S; Riedel R; Florin A; Golfmann K; Schlößer HA; Odenthal M; Buettner R; Wolf J; Hallek M; Herling M; von Bergwelt-Baildon M; Reinhardt HC; Ullrich RT
    Cancer Res; 2018 Aug; 78(15):4270-4281. PubMed ID: 29776963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy.
    Wen XF; Yang G; Mao W; Thornton A; Liu J; Bast RC; Le XF
    Oncogene; 2006 Nov; 25(52):6986-96. PubMed ID: 16715132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDYL promotes the chemoresistance of small cell lung cancer by regulating H3K27 trimethylation at the CDKN1C promoter.
    Qiu Z; Zhu W; Meng H; Tong L; Li X; Luo P; Yi L; Zhang X; Guo L; Wei T; Zhang J
    Theranostics; 2019; 9(16):4717-4729. PubMed ID: 31367252
    [No Abstract]   [Full Text] [Related]  

  • 32. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
    Tóth G; Szöőr Á; Simon L; Yarden Y; Szöllősi J; Vereb G
    MAbs; 2016 Oct; 8(7):1361-1370. PubMed ID: 27380003
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.
    Barok M; Tanner M; Köninki K; Isola J
    Cancer Lett; 2011 Jul; 306(2):171-9. PubMed ID: 21458915
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
    Spector NL; Blackwell KL
    J Clin Oncol; 2009 Dec; 27(34):5838-47. PubMed ID: 19884552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
    Huemer F; Gampenrieder SP; Schlattau A; Greil R
    Clin Breast Cancer; 2014 Feb; 14(1):e17-20. PubMed ID: 24246725
    [No Abstract]   [Full Text] [Related]  

  • 37. Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab‑refractory breast cancer model.
    Sun Y; Dey N; Brammer M; De P; Leyland-Jones B
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):733-45. PubMed ID: 23959459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The level of HER2 expression is a predictor of antibody-HER2 trafficking behavior in cancer cells.
    Ram S; Kim D; Ober RJ; Ward ES
    MAbs; 2014; 6(5):1211-9. PubMed ID: 25517306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular endothelial growth factor partially inhibits the trastuzumab-mediated antibody-dependent cellular cytotoxicity of human monocytes.
    Mimura K; Kono K; Takahashi A; Kawaguchi Y; Mizukami Y; Fujii H
    Oncology; 2007; 72(3-4):172-80. PubMed ID: 18097168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.